ResMed (RMD) Stock Price, News & Analysis

Company Overview

ResMed, founded in 1989 by engineer Peter C. Farrell, is a global leader in the development and manufacture of medical devices and cloud-connected software applications for the diagnosis, treatment and management of respiratory disorders. Headquartered in San Diego, California, the company pioneered the use of continuous positive airway pressure (CPAP) therapy for sleep apnea and has since expanded its product portfolio to address a broad range of breathing-related conditions.

The company’s core product offerings include advanced CPAP and bilevel devices, mask systems and ventilators designed for both home and hospital settings. ResMed continuously invests in research and development to enhance device comfort, efficacy and connectivity, integrating sensors and algorithms that allow for real-time monitoring of patient compliance and therapy outcomes. Its ventilator line supports critical care and noninvasive ventilation, catering to patients with chronic obstructive pulmonary disease (COPD), neuromuscular and other respiratory conditions.

Operating in more than 140 countries, ResMed serves a diverse customer base spanning sleep clinics, home healthcare providers and hospitals. The company has strengthened its position in digital health through its cloud platform, which aggregates patient data for care teams and enables remote monitoring and telehealth services. This digital ecosystem fosters greater patient engagement, streamlines clinician workflows and supports value-based care models in both mature and emerging markets.

Under the leadership of CEO Mick Farrell, who succeeded the founder in 2013, ResMed has focused on innovation, strategic acquisitions and global expansion. The executive team includes seasoned professionals in engineering, clinical affairs and global distribution, reflecting the company’s commitment to advancing respiratory care. As the prevalence of sleep apnea and chronic respiratory diseases continues to rise, ResMed aims to leverage its technology and data analytics capabilities to improve patient outcomes and reduce healthcare costs worldwide.

Key Stats

• Today's Range: $255.60 to $261.08
• 50-Day Range: $239.84 to $258.24
• 52-Week Range: $195.00 to $263.05
• Volume: 637,776 shs
• Average Volume: 965,483 shs
• Market Capitalization: $37.84 billion
• P/E Ratio: 28.97
• Dividend Yield: 0.82%
• Price Target: $259.33
• Consensus Rating: Moderate Buy

ResMed Stock Analysis - MarketRank™

ResMed scored higher than 94% of companies evaluated by MarketBeat, and ranked 75th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ResMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

ResMed has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 9.40%

Earnings Growth

Earnings for ResMed are expected to grow by 9.40% in the coming year, from $9.47 to $10.36 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ResMed is 28.97, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of ResMed is 28.97, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.20.

Price to Earnings Growth Ratio

ResMed has a PEG Ratio of 1.60. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

ResMed has a P/B Ratio of 7.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.82% of the float of ResMed has been sold short.

Short Interest Ratio / Days to Cover

ResMed has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in ResMed has recently decreased by 6.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

ResMed has a dividend yield of 0.83%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

ResMed has been increasing its dividend for 13 years.

Dividend Coverage

The dividend payout ratio of ResMed is 23.79%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, ResMed will have a dividend payout ratio of 20.46% next year. This indicates that ResMed will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.62

Percentage of Shares Shorted

6.82% of the float of ResMed has been sold short.

Short Interest Ratio / Days to Cover

ResMed has a short interest ratio ("days to cover") of 9.8.

Change versus previous month

Short interest in ResMed has recently decreased by 6.23%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.27

News Sentiment

ResMed has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for ResMed this week, compared to 17 articles on an average week.

Search Interest

4 people have searched for RMD on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

3 people have added ResMed to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,238,913.00 in company stock.

Percentage Held by Insiders

Only 0.71% of the stock of ResMed is held by insiders.

Percentage Held by Institutions

54.98% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RMD Stock Analysis - Frequently Asked Questions

How have RMD shares performed this year?

ResMed's stock was trading at $228.69 at the beginning of the year. Since then, RMD stock has increased by 12.9% and is now trading at $258.0940.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings data on Wednesday, April, 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.36 by $0.01. ResMed's revenue was up 7.9% compared to the same quarter last year.
Read the conference call transcript.

Does ResMed have any subsidiaries?

ResMed subsidiaries include Propeller Health, and Matrixcare.

Who are ResMed's major shareholders?

Top institutional investors of ResMed include Swedbank AB (0.30%), Confluence Investment Management LLC (0.08%), MassMutual Private Wealth & Trust FSB (0.05%) and Mn Services Vermogensbeheer B.V. (0.04%). Insiders that own company stock include Michael J Farrell, Robert Andrew Douglas, Brett Sandercock, David Pendarvis, Peter C Farrell, Justin Leong, Kaushik Ghoshal, Michael J Rider, Karen Drexler, Lucile Blaise and Witte Jan De.
View institutional ownership trends.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ResMed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 4/23/2025
• Record date for 6/12 Dividend: 5/08/2025
• Ex-Dividend for 6/12 Dividend: 5/08/2025
• Dividend Payable: 6/12/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 7/31/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:RMD
• CIK: 943819
• Web: www.resmed.com
• Phone: (858) 836-5000
• Fax: 858-836-5501
• Employees: 9,980
• Year Founded: 1989

Price Target and Rating

• Average Price Target for ResMed: $259.33
• High Price Target: $290.00
• Low Price Target: $180.00
• Potential Upside/Downside: +0.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.91
• Trailing P/E Ratio: 28.97
• Forward P/E Ratio: 27.25
• P/E Growth: 1.61
• Net Income: $1.02 billion
• Net Margins: 26.15%
• Pretax Margin: 31.41%
• Return on Equity: 25.67%
• Return on Assets: 18.59%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 3.41
• Quick Ratio: 2.49

Sales & Book Value

• Annual Sales: $4.69 billion
• Price / Sales: 8.08
• Cash Flow: $9.28 per share
• Price / Cash Flow: 27.81
• Book Value: $33.11 per share
• Price / Book: 7.80

Miscellaneous

• Outstanding Shares: 146,630,000
• Free Float: 145,586,000
• Market Cap: $37.84 billion
• Optionable: Optionable
• Beta: 0.77